182 related articles for article (PubMed ID: 37646663)
21. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Rodrigues JM; Hassan M; Freiburghaus C; Eskelund CW; Geisler C; Räty R; Kolstad A; Sundström C; Glimelius I; Grønbaek K; Kwiecinska A; Porwit A; Jerkeman M; Ek S
Br J Haematol; 2020 Dec; 191(5):796-805. PubMed ID: 32748433
[TBL] [Abstract][Full Text] [Related]
22. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
23. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
24. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive FISH testing using FFPE tissue microarray of primary lymph node tissue identifies secondary cytogenetic abnormalities in Mantle Cell Lymphoma.
Webb F; Morey A; Mahler-Hinder C; Georgousopoulou E; Koo R; Pati N; Talaulikar D
Cancer Genet; 2023 Jun; 274-275():75-83. PubMed ID: 37094546
[TBL] [Abstract][Full Text] [Related]
26. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
[TBL] [Abstract][Full Text] [Related]
27.
Ferrero S; Rossi D; Rinaldi A; Bruscaggin A; Spina V; Eskelund CW; Evangelista A; Moia R; Kwee I; Dahl C; Di Rocco A; Stefoni V; Diop F; Favini C; Ghione P; Mahmoud AM; Schipani M; Kolstad A; Barbero D; Novero D; Paulli M; Zamò A; Jerkeman M; da Silva MG; Santoro A; Molinari A; Ferreri A; Grønbæk K; Piccin A; Cortelazzo S; Bertoni F; Ladetto M; Gaidano G
Haematologica; 2020 Jun; 105(6):1604-1612. PubMed ID: 31537689
[TBL] [Abstract][Full Text] [Related]
28. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
[TBL] [Abstract][Full Text] [Related]
29. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
[TBL] [Abstract][Full Text] [Related]
30. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
31. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
[TBL] [Abstract][Full Text] [Related]
32. BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32).
De Angeli C; Gandini D; Cuneo A; Moretti S; Bigoni R; Roberti MG; Bardi A; Castoldi GL; del Senno L
Haematologica; 2000 Sep; 85(9):913-21. PubMed ID: 10980628
[TBL] [Abstract][Full Text] [Related]
33. Characterization of 4 mantle cell lymphoma cell lines.
Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
Arch Pathol Lab Med; 2003 Apr; 127(4):424-31. PubMed ID: 12683869
[TBL] [Abstract][Full Text] [Related]
34. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
[TBL] [Abstract][Full Text] [Related]
35. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
36. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
[TBL] [Abstract][Full Text] [Related]
37. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
[TBL] [Abstract][Full Text] [Related]
38. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.
Gao L; Harbaugh B; Parr K; Patel P; Golem S; Zhang D; Woodroof J; Cui W
Am J Clin Pathol; 2022 Jan; 157(1):119-129. PubMed ID: 34528662
[TBL] [Abstract][Full Text] [Related]
39. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
[TBL] [Abstract][Full Text] [Related]
40. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
